A5035813468- Diabetes Treatment and Management
- Cardiac Imaging and Diagnostics
- Cardiovascular Function and Risk Factors
- Heart Rate Variability and Autonomic Control
- Metabolism, Diabetes, and Cancer
- Cardiovascular Disease and Adiposity
- Diabetes Management and Research
- Diet and metabolism studies
- Blood Pressure and Hypertension Studies
- Cerebrovascular and Carotid Artery Diseases
- Cardiovascular Syncope and Autonomic Disorders
- Cardiovascular, Neuropeptides, and Oxidative Stress Research
- Receptor Mechanisms and Signaling
- Advanced MRI Techniques and Applications
- Protease and Inhibitor Mechanisms
- Renal and Vascular Pathologies
- Lipoproteins and Cardiovascular Health
- Cardiovascular Health and Disease Prevention
- Pharmacology and Obesity Treatment
- Chronic Kidney Disease and Diabetes
- Heart rate and cardiovascular health
- Cardiovascular and exercise physiology
- Antiplatelet Therapy and Cardiovascular Diseases
- Biochemical Acid Research Studies
- Cardiovascular Issues in Pregnancy
Steno Diabetes Centers
2016-2025
Capital Region of Denmark
2024
Danish Diabetes Association
2023
Novo Nordisk (Denmark)
2021-2022
OBJECTIVE Renin–angiotensin system (RAS) inhibitors decrease the urinary albumin to creatinine ratio (UACR) but are ineffective in up 40% of patients. We hypothesized that rotation through different drug classes overcomes RAS inhibitor resistance and tested this a randomized crossover trial. RESEARCH DESIGN AND METHODS assigned 26 adults with type 1 diabetes 37 2 UACR between 30 500 mg/g estimated glomerular filtration rate >45 mL/min/1.73 m2 4-week treatment periods telmisartan 80...
Anti-inflammatory effects of glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment in T2D may contribute to the cardiovascular benefits observed with GLP-1 RAs outcome studies. We investigated if RA liraglutide exerts anti-inflammatory through modulation inflammatory gene expression peripheral blood mononuclear cells (PBMCs). From 54 participants a double-blinded trial where individuals type 2 diabetes (T2D) were randomized (1.8 mg/day) or placebo for 26 weeks, sub-study was...
The mechanism behind the cardiovascular protection observed with human GLP-1 RA (glucagon-like peptide-1 receptor agonists) in type 2 diabetes is unknown. We hypothesized that treatment liraglutide had a positive effect on vascular inflammation.LIRAFLAME (Effect of inflammation type-2 diabetes: A randomized, placebocontrolled, double-blind, parallel clinical PET/CT trial) was randomized controlled trial performed at single university hospital clinic Denmark. Patients were via...
To evaluate symmetric dimethylarginine (SDMA) and asymmetric (ADMA) as risk markers of cardiovascular disease, all-cause mortality deterioration in renal function a well characterised type 2 diabetic population with microalbuminuria without symptoms coronary artery disease.200 participants followed for 6.1 years. SDMA ADMA were measured at baseline. Endpoints included (1) composite endpoint (n = 40); (2) 26); (3) decline eGFR >30% 42). Cox models unadjusted adjusted traditional factors (sex,...
Background Quantification of coronary artery inflammation and atherosclerosis remains a challenge in high-risk individuals. In this study we sought to investigate if the glucagon like peptide-1 receptor agonist liraglutide has direct anti-inflammatory effect arteries using positron emission tomography (PET) with radioactive tracer targeting activated macrophages vessel-wall. Methods Thirty randomly selected participants type 2 diabetes from placebo-controlled trial LIRAFLAME were enrolled...
Introduction Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can reduce risk of cardiovascular disease (CVD) in persons living type 2 diabetes, however the mechanisms explaining this benefit are still debated. We investigated changes plasma lipidome following treatment GLP-1 RA liraglutide. Research design and methods In a double-blind placebo-controlled trial, we randomized 102 diabetes to liraglutide or placebo for 26 weeks. Fasting blood was collected at baseline...
Type 2 diabetes is a stronger risk factor for cardiovascular disease (CVD) in women compared with men possibly due to higher susceptibility develop myocardial microvascular dysfunction. We investigated sex-dependent effects of factors on blood flow (MBF) and reserve (MFR) individuals type without overt CVD. Cross-sectional analysis prospective study including 901 recruited between 2020 2023. All participants underwent cardiac 82-Rubidium positron emission tomography/computed tomography scan...
Specific ceramides have been identified as risk markers for cardiovascular disease (CVD) years before onset of disease. Treatment with the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide has shown to induce beneficial changes in lipid profile and reduce CVD. Reducing lipotoxic lipids an antidiabetic drug therapy could be a path towards precision medicine approaches treatment complications diabetes. In this post-hoc study, investigation was carried out on effect CVD-risk...
Abstract Background Cardiac adipose tissue may have local paracrine effects on epicardial arteries and the underlying myocardium, promoting calcification affecting myocardial microcirculation. We explored whether total amount of cardiac was associated with coronary artery calcium score (CAC) flow reserve in persons type 1 or 2 diabetes healthy controls. Methods studied three groups: (1) 30 controls, (2) 60 (3) diabetes. The groups were matched for sex age. derived from retrospective analysis...
Abstract Glucagon-like peptide 1 receptor agonists have shown cardioprotective effects which been suggested to be mediated through inhibition of oxidative stress. We investigated the effect treatment with a glucagon-like agonist (liraglutide) on stress measured as urinary nucleic acid oxidation in persons type 2 diabetes. Post-hoc analysis two independent, randomised, placebo-controlled and double-blinded clinical trials. In cross-over study where diabetes microalbuminuria (LIRALBU, n = 32)...
To evaluate myocardial flow reserve (MFR) and coronary artery calcium (CAC) in persons with Type 1 diabetes or without albuminuria non-diabetic controls. MFR reflects the function of large epicardial arteries microcirculation. CAC represents structural aspects atherosclerosis. In addition, we evaluated association retinopathy, another microvascular complication.Cross-sectional study diabetes, stratified by normoalbuminuria (NORMO; n = 30) macroalbuminuria (MACRO; 30), controls (n 30)....
The link between cardiac autonomic neuropathy and risk of cardiovascular disease is highlighted as an area in which research needed. This study was undertaken to evaluate the association measures function vascular type 1 diabetes using new sensitive methods. a cross-sectional patients with diabetes, stratified by normoalbuminuria (n = 30) macroalbuminuria 30), healthy control subjects 30). Cardiac evaluated heart rate variability (HRV) indices, reflex tests (CARTs),...
Liraglutide has pleiotropic effects favouring cardiovascular and renal risks. We investigated individual responses to liraglutide in six cardio-renal risk factors examine whether one factor are associated with changes other (cross-dependency). performed secondary analysis of the LIRA-RENAL trial (n = 279) type 2 diabetes. HbA1c, body weight, systolic blood pressure (SBP), low density lipoprotein (LDL)-cholesterol, urine albumin-to-creatinine ratio (UACR) estimated glomerular filtration rate...
Quantification of vascular inflammation before and after treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may help reveal mechanistic pathways underlying the cardiovascular benefits these drugs. We assessed change in carotid arteries over 26 weeks by copper-64-labeled [1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid]-D-Phe1, Tyr3-octreotate ([64Cu]DOTATATE) PET 30 participants included a substudy double-blind trial where persons type 2 diabetes (T2D) were...
Abstract Aim To test the hypothesis that treatment with liraglutide can reduce cardiac adipose tissue. Materials and methods LIRAFLAME is a randomized placebo‐controlled, double‐blind, parallel clinical study. Participants type 2 diabetes were to 1.8 mg/d or placebo for 26 weeks. Computed tomography was performed at baseline end of evaluate tissue volume, quantified automatically. We report results secondary endpoint evaluating changes in Results A total 102 participants randomly assigned (n...
Abstract Aim Acute oxygen inhalation and slow deep breathing improve measures of autonomic function transiently in individuals with short‐duration type 1 diabetes. Our aims were to examine these interventions changes long‐duration diabetes explore interactions the presence macroalbuminuria or existing cardiovascular neuropathy. Methods Individuals ( n = 54) exposed acute inhalation, a combination both (hereafter ‘the combination’). Primary outcomes change baroreflex sensitivity heart rate...
To investigate to what extent multiple risk marker improvements confer lower of cardiovascular and kidney complications in a contemporary type 2 diabetes population.Post-hoc analysis the LEADER (n = 8638; median follow-up 3.8 years) SUSTAIN 6 3040; 2.1 outcome trials. Participants were those with baseline year-1 assessment at least one parameters interest; we pooled liraglutide-/semaglutide- placebo-treated groups categorized them by number markers clinically relevant after 1 year study...